Mariner LLC Takes Position in INmune Bio, Inc. (NASDAQ:INMB)

Mariner LLC purchased a new position in shares of INmune Bio, Inc. (NASDAQ:INMB) during the fourth quarter, HoldingsChannel reports. The firm purchased 13,836 shares of the company’s stock, valued at approximately $65,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in INMB. Wells Fargo & Company MN increased its position in shares of INmune Bio by 51.0% during the fourth quarter. Wells Fargo & Company MN now owns 6,377 shares of the company’s stock worth $30,000 after acquiring an additional 2,155 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in INmune Bio by 93.0% during the 4th quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company’s stock valued at $53,000 after purchasing an additional 5,461 shares during the last quarter. Financial Advocates Investment Management increased its holdings in INmune Bio by 14.8% during the 4th quarter. Financial Advocates Investment Management now owns 15,500 shares of the company’s stock worth $72,000 after purchasing an additional 2,000 shares in the last quarter. Rhumbline Advisers increased its holdings in INmune Bio by 16.9% during the 4th quarter. Rhumbline Advisers now owns 16,744 shares of the company’s stock worth $78,000 after purchasing an additional 2,424 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of INmune Bio in the third quarter worth approximately $79,000. Institutional investors own 12.72% of the company’s stock.

INmune Bio Trading Down 1.8 %

INMB stock opened at $6.96 on Friday. The stock has a market cap of $159.97 million, a P/E ratio of -3.19 and a beta of 1.63. The stock’s fifty day simple moving average is $7.69 and its two-hundred day simple moving average is $6.86. INmune Bio, Inc. has a 1-year low of $4.32 and a 1-year high of $11.47.

INmune Bio (NASDAQ:INMB) last released its earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, hitting analysts’ consensus estimates of ($0.43). The business had revenue of $0.05 million for the quarter. As a group, analysts forecast that INmune Bio, Inc. will post -2.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. RODMAN&RENSHAW raised INmune Bio to a “strong-buy” rating in a research report on Tuesday, January 28th. Scotiabank lifted their price objective on shares of INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Tuesday, February 11th. Rodman & Renshaw assumed coverage on shares of INmune Bio in a report on Tuesday, January 28th. They issued a “buy” rating and a $23.00 target price for the company. Finally, Maxim Group raised their price target on shares of INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $22.80.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.